載入中
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
前收盤價
US$1.01
−US$0.01 · -0.98%
盤中時間採用ET。市場資料可能有所延遲。
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
日內區間
目前US$1.01
52週區間
目前US$1.01
盤中時間採用ET。市場資料可能有所延遲。
GoAI 評分
持有
估值
43
合理估值
情緒
54
多空交錯
風險
71
高風險
動能
63
動能增強
完整 GoAI 研究
繼續查看更深入的依據、催化因素和風險。
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.
日內區間
目前US$1.01
52週區間
目前US$1.01
獲利能力占已公布營收的百分比。
營收
營業利益
淨利
| 項目（USD） | 2025會計年度 | 2024會計年度 | 2023會計年度 | 2022會計年度 | 2021會計年度 |
|---|---|---|---|---|---|
| 營收 | 3302.6萬 USD | 3862.7萬 USD | 4128.8萬 USD | 4426.1萬 USD | 3389.41萬 USD |
| 銷貨成本 | 622.2萬 USD | 710萬 USD | 474.2萬 USD | 509.8萬 USD | 364.74萬 USD |
| 毛利 | 2680.4萬 USD | 3152.7萬 USD | 3654.6萬 USD | 3916.3萬 USD | 3024.67萬 USD |
| 研究與開發 | 2082.3萬 USD | 2222.7萬 USD | 2381.7萬 USD | 1951.4萬 USD | 1540.73萬 USD |
| 銷售、一般及管理費用 | 4704萬 USD | 5635.4萬 USD | 5704.3萬 USD | 4448.2萬 USD | 3167.89萬 USD |
| 營業費用 | 7208.9萬 USD | 8272.4萬 USD | 8484.5萬 USD | 6652.4萬 USD | 4843.53萬 USD |
| 利息收入 | 726.7萬 USD | 1014.2萬 USD | 1037.6萬 USD | 391.7萬 USD | 15.08萬 USD |
| 利息支出 | — | — | — | 12.69萬 USD | 104.44萬 USD |
| 折舊和攤銷 | 514.2萬 USD | 431.5萬 USD | 456.6萬 USD | 269.8萬 USD | 142.39萬 USD |
| 營業利益 | −4528.5萬 USD | −5119.7萬 USD | −4829.9萬 USD | −2736.1萬 USD | −1818.86萬 USD |
| 淨利 | −4463萬 USD | −4105.5萬 USD | −3792.3萬 USD | −2357.1萬 USD | −1908.22萬 USD |
公司資料更新於 2026年10月11日。
已公布業績及可用的市場共識預估。
已公布業績及可用的市場共識預估。
第三方分析師預期可能變動，並非 GoAI 建議。
平均目標
US$6.00
上漲空間 494.06%報告持有此股票曝險的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI353.73萬0.00%2.3兆 USD0.03%US$381.94+0.63%
Vanguard Extended Market ETFVXF157.39萬0.00%954億 USD0.05%US$235+0.80%
Vanguard Health Care ETFVHT36.66萬0.00%220億 USD0.09%US$319.01+1.64%
EA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSM6萬0.05%1.17億 USD0.73%US$15.9402+0.25%Vanguard Morningstar Total Stock Market ETFVTIVanguard Extended Market ETFVXFVanguard Health Care ETFVHTEA Series Trust - EA Bridgeway Ultra-Small Company Market ETFBUSMAI 生成內容及延遲市場資料僅供資訊與教育用途，不構成投資建議。
